Exopharm

Technology Platform and Partnering Strategy

Exopharm is investing in three interrelated technologies to support partnering transactions:

  • Precision medicine EEVs satisfy the needs of well-funded pharmaceutical and biotechnology companies. With our EV engineering technologies (LOAD for the addition of RNA and EVPS for the addition of proteins) and LEAP, our aim is to be an active partner with major pharmaceutical companies in the rapidly developing EEV field.
  • Regenerative medicine NEVs can be used to treat conditions that affect health across an entire life span, including mobility, sensory acuity and the like.
  • Our manufacturing expertise and intellectual property solve key EV manufacturing problems and demonstrate our leadership in this burgeoning space.

eVICI and Research

Exopharm is rapidly expanding its exosome portfolio, from engineering EVs to isolation, characterisation and functional research. If you are conducting research into EVs, it is likely that the eVICI platform could accelerate your work. If you have unique IP in the field, it may have value for Exopharm. Contact us to initiate in-licensing or collaborative research discussions: partnering@exopharm.com

Partnering with Exopharm

Exopharm is actively seeking partnerships with biopharmaceutical companies with interest in bringing exosome-based medicines to their therapeutic areas.

What Exopharm brings to partnerships:

Clinical-scale manufacturing

LEAP Technology enables:
-Fast and cost-effective exosome isolation from biofluids or culture media including platelets, mesenchymal stem cells, iPSCs, other cells (e.g. CAR-T cells)
-Maximum yield from micro-liter bench-scale to multi-liter bioreactor scale volumes with full preservation of exosome integrity
-GMP purification of exosomes for clinical applications

LOADing specialised cargo

Exopharm’s loading technology enables insertion of specially-designed nucleic acids to the payloads of EVs. Nucleic acids including mRNA, RNAi and siRNA can modify how cells operate.

Targeted delivery

Exopharm’s proprietary technology enables the attachment of custom proteins to the surface of EVs. This allows targeting of EVs to selected cell types.

Analytics & characterization

Exopharm holds a comprehensive suite of EV characterization and analysis technologies along with deep experience in EV medicine formulation, assays and release.

Dedicated BD Scientists

Exopharm is so committed to making partnerships successful that we have senior researchers directly integrated into our partnership team. Partnering with Exopharm means fast and meaningful results that will de-risk and size opportunities quickly.

A partnership with Exopharm can:

  • Translate EV potential in your target therapeutic area (such as neurology, cancer, or autosomal diseases) into legitimate development plans
  • Quickly de-risk EV investments
  • Accelerate product-to-market timelines
  • Solve manufacturing challenges early to kick-start non-clinical and clinical trials
  • Provide a layer of patent protection to future offerings, either through new composition of matter IP using EVs (extend patent life of APIs) or by adding proprietary processes early in product development

Partner with Exopharm to jointly push the boundaries in regenerative medicine and to expedite the development of exosome-based therapies for patients.

Contact us to initiate partnering discussions: partnering@exopharm.com